Giuseppe
Emeritus
[Source: Nature Medicine, full text: (LINK). Extract.]
------
The Ongoing Battle Against Influenza: Drug-resistant influenza viruses: why fitness matters
Anne Kelso<SUP>1 </SUP>& Aeron C Hurt<SUP>1</SUP>
<SUP></SUP>
Journal name: Nature Medicine / Volume: 18, Pages: 1470?1471 / Year published: (2012) / DOI: doi:10.1038/nm.2954
Published online 05 October 2012
Influenza viruses can spread explosively and cause devastating disease. Of the few drugs we have to reduce the impact of influenza, oseltamivir is the most widely used and stockpiled. However, just over four years ago, A(H1N1) influenza viruses circulating in humans rapidly acquired a mutation that conferred oseltamivir resistance without?
(?)
Affiliations
(1) Anne Kelso and Aeron C. Hurt are at the World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia.
Competing financial interests: The World Health Organization Collaborating Centre for Reference and Research on Influenza receives antiviral drugs free of charge from Hoffman-la Roche, GlaxpSmithKline, Biocryst Pharmaceuticals and Daiichi Sankyo for laboratory use for surveillance and research on antiviral drugs susceptibility. The Centre has also undertaken collaborative studies with Biota Holdings, for which Biota has provided antiviral drugs but not funds.
Corresponding author: Correspondence to: Anne Kelso
-<SUP></SUP>
Journal name: Nature Medicine / Volume: 18, Pages: 1470?1471 / Year published: (2012) / DOI: doi:10.1038/nm.2954
Published online 05 October 2012
Influenza viruses can spread explosively and cause devastating disease. Of the few drugs we have to reduce the impact of influenza, oseltamivir is the most widely used and stockpiled. However, just over four years ago, A(H1N1) influenza viruses circulating in humans rapidly acquired a mutation that conferred oseltamivir resistance without?
(?)
Affiliations
(1) Anne Kelso and Aeron C. Hurt are at the World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia.
Competing financial interests: The World Health Organization Collaborating Centre for Reference and Research on Influenza receives antiviral drugs free of charge from Hoffman-la Roche, GlaxpSmithKline, Biocryst Pharmaceuticals and Daiichi Sankyo for laboratory use for surveillance and research on antiviral drugs susceptibility. The Centre has also undertaken collaborative studies with Biota Holdings, for which Biota has provided antiviral drugs but not funds.
Corresponding author: Correspondence to: Anne Kelso
------